Fenoldopam mesylate (Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.

[4] Since fenoldopam is an intravenous agent with minimal adrenergic effects that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant chronic kidney disease.

The renal effect of fenoldopam and dopamine may involve physiological antagonism of the renin-angiotensin system in the kidney.

[10] Adverse effects include headache, flushing, nausea, hypotension, reflex tachycardia, and increased intraocular pressure.

[4][11] Fenoldopam mesylate contains sodium metabisulfite, a sulfite that may rarely cause allergic-type reactions including anaphylactic symptoms and asthma in susceptible people.